Cargando…
Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir
BACKGROUND: Until now, no risk score could predict hepatocellular carcinoma (HCC) in nucleos(t)ide analog (NA)-treated Asian patients. METHODS: We enrolled 1325 NA-naïve chronic hepatitis B patients with entecavir monotherapy for >12 months, with 883 and 442 patients randomly assigned to the deve...
Autores principales: | Chen, Chien-Hung, Lee, Chuan-Mo, Lai, Hsueh-Chou, Hu, Tsung-Hui, Su, Wen-Pang, Lu, Sheng-Nan, Lin, Chia-Hsin, Hung, Chao-Hung, Wang, Jing-Houng, Lee, Mei-Hsuan, Peng, Cheng-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696194/ https://www.ncbi.nlm.nih.gov/pubmed/29190928 http://dx.doi.org/10.18632/oncotarget.21369 |
Ejemplares similares
-
On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma
por: Wang, Hung-Wei, et al.
Publicado: (2020) -
Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment
por: Ma, Te-Ling, et al.
Publicado: (2019) -
Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B
por: Peng, Cheng-Yuan, et al.
Publicado: (2017) -
The Changes of Liver Stiffness and Its Associated Factors for Chronic Hepatitis B Patients with Entecavir Therapy
por: Kuo, Yuan-Hung, et al.
Publicado: (2014) -
Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse
por: Tseng, Tzu-Ning, et al.
Publicado: (2022)